Given that access to ophthalmologists can be a significant bottleneck for patients, it is acceptable and practical for routine monitoring of mirvetuximab-related ocular side effects to be managed by optometrists. This pragmatic approach improves accessibility while ensuring patient safety.

While the antibody-drug conjugate (ADC) Tivdac offers a new treatment avenue, it introduces significant logistical hurdles. The requirement for a specialist eye exam at every single visit creates a major access barrier for clinics without integrated ophthalmology services, highlighting how non-clinical factors can limit the real-world application of effective drugs.

Clinicians must weigh the immediate benefit of using community-accessible belantumab against the risk of reducing the efficacy of future BCMA-targeted therapies like CAR-T or bispecifics. This decision hinges on a patient's ability to travel and access advanced care, creating a complex treatment sequencing challenge.

Clinicians mitigate Belantamab's ocular toxicity by extending dosing intervals to every 8-12 weeks. This is effective due to the drug's long half-life and often allows vision to recover between doses, sometimes even deepening responses without sacrificing disease control.

Data from the DREAM 7 trial reveals that holding belantamab doses for 12 weeks or longer to manage ocular toxicity did not negatively impact progression-free survival (PFS). Responding patients often maintain their response, challenging the conventional wisdom that strict dosing schedules are paramount for efficacy.

GYN oncology nurses are accustomed to GI and hematologic side effects. With mirvetuximab, they must now manage eye-related issues, requiring patient education on prophylactic eye drops and coordination with ophthalmologists for regular exams.

For required ocular monitoring with certain ADCs, patients do not need to see a specialist ophthalmologist. An optometrist, including those at accessible and lower-cost retail locations, is fully qualified to perform the necessary exams. This practical tip helps mitigate financial toxicity and improves patient access to care.

Clinicians are successfully managing Belantamab's primary side effect, keratopathy, by using lower starting doses and extending dosing intervals to every 8 or 12 weeks once a response is seen. This maintains efficacy while significantly improving tolerability for patients.

Integrating next-gen SCLC treatments like T-cell engagers requires more than education; it demands a physical and operational overhaul. Community practices must build infrastructure for 24-hour observation and establish proactive partnerships with specialists like ophthalmologists to manage novel toxicities.